A new mass spectrometer for studying proteins in cancer and Alzheimer's disease
Official title: A High Throughput and High Sensitivity Mass Spectrometer for Proteomics Studies on Human Diseases
Funded at Massachusetts General Hospital · NIH-10868145 · Data updated 2026-11-12
This study is looking at how proteins linked to cancer and Alzheimer's disease work and interact, using a special tool to help find better ways to diagnose and treat these conditions for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,352,820 |
| NIH project number | 1S10OD036457-01 |
| Project ID | NIH-10868145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancer or Alzheimer's disease who are interested in contributing to advancements in their treatment.
✕Less likely to help
Patients with conditions unrelated to cancer or Alzheimer's disease may not receive any benefit from this research.
What this research studies
This research focuses on utilizing a cutting-edge mass spectrometer to analyze proteins related to cancer and Alzheimer's disease. By measuring the entire set of proteins in biological systems, researchers aim to understand how these proteins behave and interact in the context of these complex diseases. The study will enhance the sensitivity and throughput of proteomics, allowing for more detailed insights into protein modifications and functions that are crucial for disease understanding and treatment. Patients may benefit from improved diagnostic tools and targeted therapies developed from this advanced proteomics technology.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and targeted treatments for patients with cancer and Alzheimer's disease.
How similar studies have gone: Previous research has shown that advancements in proteomics technology can significantly enhance our understanding of complex diseases, indicating a promising potential for this novel approach.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Haas, Wilhelm — Massachusetts General Hospital
- Study coordinator: Haas, Wilhelm
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.